MREO News and Press, Mereo BioPharma Group

2024-07-25 07:00:04 ET Summary The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology...

2024-06-30 09:25:12 ET Summary Mereo BioPharma Group plc has seen a rebound in its stock over the past year, with positive analyst commentary in the second quarter. The company is focused on developing therapeutics for oncology and rare diseases, with a lead candidate for Osteogen...

2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...

2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...

2024-06-13 16:48:30 ET More on Mereo BioPharma Group Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy Mereo BioPharma Group GAAP EPS of -$0.04 Seeking Alpha&...

2024-06-12 07:00:18 ET More on Mereo BioPharma, Ultragenyx, etc. Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript Mereo BioPharma's Pipeline Promise Vs. Valuation And ...

14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment resulted in continued, substantial improvements in bone mineral density (BMD) with a me...

2024-06-06 15:42:20 ET Summary Ultragenyx Pharmaceutical Inc. revenues from regulatory approved drugs in Q1 of 2024 were $109 million, representing sales growth of 8% compared to the same time period in 2023. Setrusumab is an anti-sclerostin monoclonal antibody being developed for...

LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in...